5-Amino-1MQ Dosage: Oral vs Injection, Cycle & Safety

5-Amino-1MQ Dosage: Oral vs Injection, Cycle & Safety. 5-Amino-1MQ dosage guide: oral vs injection, 50-150mg research ranges, cycle length, half-life, and safety. Research context with cited sources. Key Takeaways 5-Amino-1MQ is a small molecule, not a peptide — an NNMT inhibitor sold alongside research peptides. It blocks an enzyme that consumes the vitamin-B3 needed to make NAD+. Oral is the practical route: community research context centers on 50–150mg per day in capsule form. The injectable vial format exists but the volume math makes it awkward at meaningful doses. All published evidence is preclinical — cell and mouse studies. There are no completed human clinical trials of 5-Amino-1MQ, and no human dose has ever been validated. Cycle length is undefined by research. Community protocols of 4–12 weeks with breaks are convention, not evidence. Safety profile is only as good as the mouse data: published animal work reports no significant toxicity at studied doses, but that cannot be extended to humans. 5-Amino-1MQ dosage searches have grown with the compound's popularity in metabolic and longevity research circles — and most of what ranks is forum speculation presented as protocol. This guide separates what the published research actually did from what the research community discusses, because the two barely overlap. The honest framing first: 5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule NNMT inhibitor, not a peptide, despite being sold in peptide storefronts. There are no completed human trials. Everything below describes preclinical research parameters and community-reported conventions for comparison purposes only. Quick Start: The Research Picture at a Glance Parameter Published research / community context Compound class Small molecule, NNMT inhibitor (not a peptide) Common research route Oral capsules (community); injection vial format exists Community oral range 50–150 mg per day, morning Vial format 10mg vials typical; awkward dosing volume by injection Half-life Short — no human pharmacokinetic data published Cycle length Undefined by research; community uses 4–12 weeks with breaks Human evidence None — preclinical (cell, mouse) only Regulatory status Not FDA-approved; research-use only What 5-Amino-1MQ Actually Does NNMT (nicotinamide N-methyltransferase) is an enzyme highly expressed in white fat tissue. It consumes nicotinamide — the vitamin-B3-derived molecule the body needs to synthesize NAD+, the cellular energy currency. When NNMT runs high in fat tissue, NAD+ availability drops, and fat cells shift toward storage rather than oxidative metabolism. 5-Amino-1MQ blocks NNMT. In the original identification work, a fat-cell–specific screen found the compound could reduce fat-cell viability while sparing other cell types, and subsequent research showed NNMT inhibition raised NAD+ availability and shifted fat tissue toward a leaner metabolic profile. That is the entire mechanism story: block the enzyme, preserve the B3 substrate, raise NAD+ inside the cell. Oral vs Injection: The Practical Divide This is the question researchers actually face, and the answer is almost always oral. The Oral Route (Community Standard) Community research context centers on 50–150mg per day in capsule form, taken in the morning . The oral route exists because 5-Amino-1MQ is a small, membrane-permeable molecule — the same property that lets it cross into cells makes oral delivery plausible. Most community-reported protocols start at 50mg daily and adjust within the range based on tolerance. The Vial Route (Why It's Awkward) 5-Amino-1MQ is sold in 10mg research vials . Here's the math problem: a 50mg "research amount" requires five vials' worth of material, reconstituted into a solution concentrated enough to inject a reasonable volume. Researchers who use the vial format typically reconstitute each 10mg vial with 1mL bacteriostatic water (10mg/mL) and pool the solution — at which point the oral capsule equivalent is cheaper and simpler. The injectable route is discussed for theoretical bioavailability reasons, but no published pharmacokinetic study establishes that advantage in any model. For most researchers the oral format is the practical choice; the vial format exists mainly because peptide storefronts sell in vials. Cycle Length: What the Evidence Says (Almost Nothing) No published trial — human or animal — has established a 5-Amino-1MQ cycle length. Community protocols typically describe 4–12 week cycles with 2–4 week breaks , modeled on conventions from other metabolic compounds rather than on any 5-Amino-1MQ-specific finding. The longest published animal feeding study ran roughly 8 weeks of continuous dosing in mice with no reported toxicity signal at studied doses. Whether that maps to human cycling is unknown. Anyone treating 4 weeks on / 2 weeks off as an evidence-based protocol is dressing convention in research language. Half-Life and Timing No human pharmacokinetic data exists. In animal and cell models the compound's inhibitory activity is consistent with a short effective duration, which is why community protocols divide or take the daily amount in the morning rather than spacing it. Morning timing is also favored because of a second community observation — that 5-Amino-1MQ can be alerting — though that effect is anecdotal and unstudied. Dosage Chart: Community Ranges by Experience Level Community tier Daily amount Notes Entry 50 mg/day Most common starting point in community logs Standard 100 mg/day The most-reported community amount Upper 150 mg/day Top of the community range; tolerance-dependent Read that table correctly: these are community-reported conventions, not validated doses. The only doses with published context are the milligram-per-kilogram amounts used in mouse studies, which do not convert to a human protocol. Side Effects and Safety Published animal work reports no significant toxicity at the doses studied, and the compound's mechanism — blocking an enzyme rather than activating a receptor — is theoretically gentler than many research compounds. But the safety ceiling is exactly as high as the mouse data, and no further. Reported community observations include occasional alertness/insomnia when dosed late in the day, mild appetite changes, and standard injection-site irritation for those using the vial route. None of these are systematically documented. Researchers should treat 5-Amino-1MQ's human safety profile as unknown rather than clean. Human Evidence: The Part Most Pages Skip There are no completed human clinical trials of 5-Amino-1MQ. The compound's entire evidence base is preclinical: the original fat-cell identification work, follow-up mouse studies on high-fat-diet models, and cell-culture mechanistic research. Marketing that describes human fat-loss results is extrapolating from mice. That does not make 5-Amino-1MQ uninteresting — the NNMT mechanism is genuinely one of the more credible metabolic targets in recent preclinical literature. It makes it unvalidated. Who Should Avoid It Anyone outside a qualified research context. Specifically flagged by the mechanism: the compound's interaction with B-vitamin metabolism means anyone studying it should baseline metabolic markers, and its NAD+ pathway involvement puts it in the same research bucket as other cellular-energy compounds. These are research-design considerations, not medical guidance. Sourcing Notes for Researchers 5-Amino-1MQ is listed in 10mg research vials at Peptide Partners ($56 at the time of writing, code KLIKOOGQWG for 10% off). Because the compound is usually dosed orally in community practice, most researchers source capsules rather than vials — check current catalog format before ordering, and verify batch COAs whichever format you choose. This page is educational research context, not medical advice, not a dose recommendation, and not a human-use protocol. 5-Amino-1MQ is sold for in-vitro laboratory research only. Sources and Research Notes Neidert LE, et al. A small molecule inhibitor of Nicotinamide N-methyltransferase for the treatment of metabolic disorders. PMC5826917 Garge N, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. PMC5826726 Wang S, et al. Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice. Sci Rep. 2022. PMID 35013352 PeptideStack page context: visitors can use the header navigation to reach the product catalog, blog, calculators, supplier pages, discount-code pages, contact page, legal policies, privacy policy, terms, and research disclaimer. The site is organized around research peptide education, supplier transparency, product comparison, vendor review content, discount-code tracking, and calculator tools for reconstitution or unit conversion research planning. PeptideStack separates research-use-only peptide information from FDA-approved medication and licensed telehealth pathways. Research peptide pages are informational and are not medical advice, prescription guidance, dosing instructions, treatment recommendations, or instructions for human consumption. Many pages include affiliate disclosures because PeptideStack may earn a commission when visitors click external supplier or telehealth links. That commission does not change the price paid by visitors and does not mean PeptideStack manufactures, sells, distributes, compounds, or ships peptides or medications. Supplier and product pages should be evaluated for third-party testing, batch-specific certificates of analysis, named laboratory verification, transparent pricing, realistic delivery expectations, payment security, refund policies, support quality, and consistent research-use-only labeling. Blog pages connect related guides, comparison articles, FDA approval status explainers, safety context, legality resources, product pages, vendor reviews, and calculator tools so visitors can keep researching without relying on a single supplier claim. Calculator pages are educational tools for laboratory planning and should be cross-checked against professional protocols, institutional requirements, and applicable laws. Legal and disclaimer pages explain the boundaries of PeptideStack content and the responsibility of visitors who evaluate third-party vendors. The rendered interface may add interactive details such as mobile navigation labels, product tabs, share buttons, related article cards, disclosure boxes, call-to-action buttons, vendor selectors, copy-code controls, email-code forms, footer navigation, and status labels. The static HTML fallback includes this context so the same page purpose is understandable before the JavaScript application finishes loading. Visitors should treat PeptideStack as a research and comparison starting point. Final supplier evaluation should include direct review of the external vendor website, current product availability, checkout terms, applicable laws, institutional requirements, and any third-party laboratory documentation available for the exact product or batch being considered. Footer resources repeat important sitewide context: PeptideStack is independent, affiliate-supported, research-focused, and not a pharmacy or manufacturer. Pages may include links to the iOS app, calculators, blog hubs, product hubs, supplier comparisons, support contact, and policy documents. This repeated context is intentionally available in the raw HTML for crawlers that inspect a page before executing the React bundle. Raw HTML also includes page summaries for mobile crawlers using JavaScript rendering, desktop crawlers comparing source to rendered output, accessibility tools, and no-script visitors. The fallback is replaced by the React app in normal browsers but keeps the source document aligned with the visible page topic. This fallback keeps source HTML and rendered HTML closer for crawl diagnostics and SEO audits across crawled pages, routes, reports, and recrawls.